<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The author describes the results of treatment of 299 patients with clinical evidence of cerebral <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> receiving three groups of antiatherosclerotic agents: improving cerebral blood flow (naftidrofuryl, cinnarazine, pyridinol <z:chebi fb="1" ids="13941">carbamate</z:chebi>, low-molecular <z:chebi fb="0" ids="52071">dextran</z:chebi>), normalizing <z:chebi fb="23" ids="18059">lipid</z:chebi> metabolism (<z:chebi fb="0" ids="3750">clofibrate</z:chebi>, heparinoid, <z:chebi fb="0" ids="22470">alpha-tocopherol</z:chebi>, Procetophen) and improving the metabolism of nerve cells (piracetam, pyritinol) </plain></SENT>
<SENT sid="1" pm="."><plain>After a statistical analysis of the results of the author evaluated the effectiveness of these drugs in various groups and suggested practical conclusions and treatment schedules in various forms of cerebral <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> </plain></SENT>
</text></document>